Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study

BACKGROUND: Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Andrew, Roberts, Andrew, Kennedy, Nola, Ravera, Christina, Cremers, Serge, Bilic, Sanela, Neeman, Terry, Copeman, Michael, Schran, Horst, Lynch, Kevin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2330021/
https://www.ncbi.nlm.nih.gov/pubmed/18377658
http://dx.doi.org/10.1186/1472-6904-8-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2330021/
https://www.ncbi.nlm.nih.gov/pubmed/18377658
http://dx.doi.org/10.1186/1472-6904-8-2

Ejemplares similares